Our bioinformatics analyses highlighted the concomitant dysregulation of PAM, ER, and CDK pathway activities in the HR+/HER2- BC subtype and the potential of targeting multiple dysfunctions with a PAM pathway inhibitor added to the standard of care with ET and CDK4/6 inhibitors. This evidence concerns the gene ESR1 and breast cancer.